Holen Sie sich die Stockscreener-App
0.6887
28.97%
0.1547
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BCLI?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.534
Offen:
$0.65
24-Stunden-Volumen:
2,518
Relative Volume:
3.13
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.31M
KGV:
-0.5738
EPS:
-1.2003
Netto-Cashflow:
$-6.98M
1W Leistung:
+28.97%
1M Leistung:
+28.97%
6M Leistung:
-68.49%
1J Leistung:
-87.10%
1-Tages-Spanne:
$0.65
$0.6966
1-Wochen-Bereich:
$0.65
$0.6966
52-Wochen-Spanne:
$0.534
$0.6966
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Firmenname
Brainstorm Cell Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare BCLI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
0.6966 | 0 | 0 | -10.31M | -6.98M | -1.2003 |
VRTX
Vertex Pharmaceuticals Inc
|
426.40 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
708.50 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.49 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.43 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.22 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-02-04 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-11-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2016-12-19 | Bestätigt | Maxim Group | Buy |
| 2015-12-22 | Bestätigt | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Aktie (BCLI) Neueste Nachrichten
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Quantisnow
Top Synthetic Stem Cells MarketAthersys, Inc., BrainStorm - openPR.com
Leading Companies Reinforcing Their Presence in the Stem Cell Therapy for Multiple Sclerosis Market - openPR.com
Aug Shorts: What is the target price for Brainstorm Cell Therapeutics Inc stockMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Layoff Watch: Whats the profit margin of Brainstorm Cell Therapeutics IncGold Moves & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Brainstorm Cell Therapeutics Inc. (BCLI) Stock Price | Live Quotes & Charts | OTCQB - StocksToTrade
Brainstorm Cell Therapeutics 2025 10-K: $0.0M Revenue, $(1.11) EPS - TradingView — Track All Markets
ALS therapy pivot: BrainStorm (BCLI) pulls BLA, wins FDA SPA for new Phase 3b - Stock Titan
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
BrainStorm Cell (OTCQB: BCLI) posts 2025 loss, tight cash and equity deficit - Stock Titan
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update - ChartMill
Growth Value: What is the target price for Brainstorm Cell Therapeutics Inc stock2026 Year in Review & Capital Efficient Trade Techniques - baoquankhu1.vn
Gap Down: Whats the profit margin of Brainstorm Cell Therapeutics Inc2026 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Pullback Watch: Is Brainstorm Cell Therapeutics Inc in a long term uptrend2026 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Breakout Zone: Does Brainstorm Cell Therapeutics Inc have declining or rising EPS2026 Breakouts & Reliable Breakout Stock Forecasts - baoquankhu1.vn
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn® - Nasdaq
If You Invested $1,000 in Brainstorm Cell Therapeutics I (BCLI) - Stock Titan
Tech Rally: Is Brainstorm Cell Therapeutics Inc stock risky to hold nowEarnings Performance Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 Delveinsight Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - menafn.com
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Insider Buy: Is Olema Pharmaceuticals Inc forming bullish engulfing patterns2026 Short Interest & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Weekly Recap: How do insiders feel about Brainstorm Cell Therapeutics Inc2026 Short Interest & Community Trade Idea Sharing - baoquankhu1.vn
Maxim Group downgrades Brainstorm Cell Therapeutics (BCLI) - MSN
S P Trends: Is Brainstorm Cell Therapeutics Inc in a long term uptrend2025 Top Gainers & Weekly Breakout Watchlists - baoquankhu1.vn
BCLI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Brainstorm Cell Therapeutics Adds Shares to Equity Incentive Plan - TipRanks
Brainstorm Cell Therapeutics Arranges Up to $1.0 Million Private Placement at $0.60, Adds Warrants - TradingView
Brainstorm Cell (BCLI) launches $1M private placement and adds 5.5M incentive shares - Stock Titan
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program - GuruFocus
Brainstorm Cell secures second $1M private placement this month By Investing.com - Investing.com Nigeria
Brainstorm Cell secures second $1M private placement this month - Investing.com
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February - Nasdaq
Aug Outlook: Whats the profit margin of Brainstorm Cell Therapeutics IncPortfolio Update Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
BCLI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Brainstorm Cell Therapeutics Inc. announced that it expects to receive $1 million in funding - marketscreener.com
Brainstorm Cell secures $1M strategic financing - MSN
Brainstorm Cell raises $1M in private placement at premium pricing - Investing.com Nigeria
Loss Report: Is Brainstorm Cell Therapeutics Inc stock undervalued right now2025 Short Interest & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Published on: 2026-02-20 18:26:53 - mfd.ru
Brainstorm Cell Therapeutics announces $1 million strategic financing at premium to market - marketscreener.com
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market - TradingView
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market - Financial Times
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - The Manila Times
Setup Watch: What is the target price for Brainstorm Cell Therapeutics Inc stockTrade Volume Summary & Low Risk Growth Stock Ideas - baoquankhu1.vn
Market Outlook: Is Brainstorm Cell Therapeutics Inc. stock risky to hold nowJuly 2025 Reactions & Smart Money Movement Tracker - baoquankhu1.vn
Tech Rally: Can Brainstorm Cell Therapeutics Inc be the next market leaderJuly 2025 Volume & Capital Protection Trade Alerts - baoquankhu1.vn
Brainstorm Cell Therapeutics Announces New Private Placement Financing - The Globe and Mail
What is the target price for Brainstorm Cell Therapeutics Inc. stockJuly 2025 Update & Fast Gain Swing Trade Alerts - mfd.ru
Brainstorm Cell Therapeutics Signs Securities Purchase Agreement With Accredited Investor - TradingView
Is Brainstorm Cell Therapeutics Inc. in a long term uptrend2025 Investor Takeaways & Expert Curated Trade Setup Alerts - mfd.ru
Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica - GlobeNewswire
Finanzdaten der Brainstorm Cell Therapeutics Inc-Aktie (BCLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.78%
0.81%
Kapitalisierung:
|
Volumen (24h):